Aastrom Adds Revenues Through $6.5M Regen Med Buy From Sanofi
This article was originally published in The Pink Sheet Daily
Executive Summary
The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.
You may also be interested in...
Biopharma Dealmaking Quarterly Statistics, Q2 2014
Biopharma financing totaled $7.2 billion, a 36% decrease from Q1; 36 completed M&As had a combined potential value reaching $116 billion, more than three-and-a-half times the previous quarter; 84 biopharma alliances, together totaling $7.7 billion in potential pre-commercialization value, showed a significant jump from Q1’s $1.9 billion aggregate.
Deal Watch: Much Activity Beyond GSK/Novartis/Lilly Pacts And Valeant/Allergan Bid
In addition to the mega-deal, Valeant’s latest acquisition gambit and the Pfizer/AstraZeneca rumors, the hectic week saw Celgene pay a huge upfront for a Phase III Crohn’s candidate, Aastrom purchase Sanofi’s regenerative medicine business and The Medicines Company add to its surgical products portfolio.
Aastrom Stands Behind Its Decision To Shift Gears In Late Stages
The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.